CDP323 Biomarker Study

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Collaborator: Biogen

Criteria

Inclusion Criteria:

• Female and male subjects aged 18-65 years

• Relapsing form of MS with at least one clinical relapse in the 24 months before screening;

• Screening EDSS score of 0-6.5;

• Must be fully immunocompetent

• Female subjects of childbearing potential must agree to practice contraception methods

Exclusion Criteria:

• Any conditions that could interfere with the contrast-enhanced MRI;

• Any clinically significant disease state or findings other than MS;

• Any clinically significant deviation from the pre-defined ranges for laboratory tests;

• Concomitant treatment with MS disease modifying drugs